ESMO 2022 | The evolution of HER2-low-positive breast cancer as a clinical subtype

Mattia Rediti, MD, Institut Jules Bordet, Anderlecht, Belgium, talks on the molecular characteristics and prognosis of HER2-low breast cancer as a distinct subtype. In addition to HER2-low as a potential target, identifying patients who are HER2-negative will benefit clinicians in terms of delivering suitable therapies. Patient selection can additionally be enhanced by expanding testing beyond immunohistochemistry and incorporating genetic testing. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.